While preclinical studies suggest a link between PCSK9 inhibition and reduced tumor growth, robust clinical trials are needed to clarify inclisiran’s potential role in oncological prevention and its broader impact on cancer-related metabolic pathways [183,184,185]. The gene discussed is PCSK9; the disease is neoplasm.